By API User
A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. HEIDELBERG, GERMANY / ACCESSWIRE / November 7, 2023 / BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble … Continued
By API User
Bisantrene in combination with fludarabine and clofarabine administered over four days induced a clinical response in 6 of 15evaluable patients (40%) with advanced relapsed or refractory Acute Myeloid Leukaemia, with five patients receiving apotentially curative stem cell transplant The bisantrene combination was found to be safe and well tolerated without clinically relevant cardiotoxicity or tumour lysissyndrome The trial abstract has been peer-reviewed and the interim results selected for presentation at the prestigious American Society of Hematology 65th Annual Conference, 9-12 December 2023. 6 November 2023 – Race Oncology Limited (“Race”) is pleased to announce interim clinical results from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory Acute Myeloid Leukaemia (R/R AML) patients. The trial is running at the Sheba Medical Centre, Israel, under the supervision of key opinion leader Professor Arnon Nagler. Results of this trial have been chosen by the conference … Continued
By API User
Highlights Results from the first clinical validation study of the CleoDX Triage Test, performed in a 334 patient cohort, have been published in the peer-reviewed journal “Cancers” The article, entitled ‘A novel predictive multi-marker test for the pre-surgical identification of ovarian cancer’ provides a detailed overview of the high performance of Cleo’s ovarian cancer diagnostics … Continued
By API User
BioMed X inaugurates its new institute in the USA with a research project on complex ex vivo models of tissue inflammation in collaboration with AbbVie. NEW HAVEN, CT / ACCESSWIRE / October 31, 2023 / BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be … Continued
By API User
Australian Red Cross is thrilled to announce a significant milestone in its mission to leverage cutting-edge technology to address critical humanitarian and social issues. Two innovative startups from the Humanitech Lab’s pilot phase, Kara Technologies and AirSeed, have been selected as recipients of scale-up funding, with support from founding partner Telstra Foundation. In a joint … Continued
By API User
A new artificial heart designed and built by Monash University students is on its way to the USA to compete against the world’s best at a global artificial heart competition to help combat one of the world’s biggest killers – heart failure. Final year engineering and biomedical science undergraduate student Georgia Brooks is the … Continued
By API User
For immediate release The scientific co-founders of global biotechnology company, BioNTech, who launched the world’s first approved Covid-19 vaccine, and world-renowned infectious diseases expert and Director of the Peter Doherty Institute for Infection and Immunity (Doherty Institute), were today awarded prestigious Honorary Doctorates by La Trobe University for their immense contributions to mRNA vaccine … Continued
By API User
Key points Eight healthy volunteers have now received three doses of AD-214 in Phase I extension study Study investigators continue to report no safety concerns, confirming favourable tolerability profile from lower doses Headline pharmacokinetic and receptor engagement data still anticipated November 2023 for ongoing, advancing partnering discussions MELBOURNE Australia, 23 October 2023: AdAlta Limited (ASX:1AD), the clinical stage company developing novel protein and cell therapeutic products from its i-body® platform, is pleased to report that all healthy volunteers in its AD-214 Phase I extension study have now successfully received three doses, enabling pharmacokinetic and receptor engagement analysis to be completed on schedule and … Continued
By API User
LUXEMBOURG / ACCESSWIRE / October 20, 2023 / Moolec Science SA (NASDAQ:MLEC) a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, today reported its Business Update for the fourth quarter of Fiscal Year 2023 ended June 30, 2023. The main highlights of the Company’s business update are as follows: … Continued
By API User
LUXEMBOURG / ACCESSWIRE / October 17, 2023 / Moolec Science SA (NASDAQ:MLEC; "Company"; "Moolec”), a science-based food ingredient company, announced today that it has entered into agreements to issue a convertible note due 2026 to Grupo Insud ("Insud") in a principal amount of approximately US $21 million (the "Insud Convertible Note") with a strike price … Continued
